Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXS-4728A in Isolated Rapid Eye Movement Sleep Behavior Disorder
NCT05904717Phase 2Active, not recruiting
- Sponsor
- Syntara Limited
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in REM sleep behavior disorder (RBD) comparing PXS-4728 with Placebo (2 arms). Primary endpoints: Reduction of microglial activation across striato-cortical regions at 12 weeks and Adverse Events at 24 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
PXS-4728A
03
Conditions
REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT05904717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904717.